“‘Beyond amyloid’: A look at what’s next in Alzheimer’s research,” by Damian Garde, STAT

“t’s neuroscience’s oldest and most acrimonious debate. On one side, scientists who aver that blasting away toxic plaques called amyloid is the best path toward treating Alzheimer’s disease. On the other, frustrated skeptics ready to ditch the amyloid hypothesis once and for all. But a parade of failed clinical trials has seeded a growing middle ground of agnostics and stoked a bevy of new research efforts, as “the field in general — and our pharma colleagues — are recognizing that they need to think beyond amyloid,” said Dr. David Knopman, a neurologist at the Mayo Clinic. Here’s a look at some of the most interesting ideas from the beyond.”

LTC Comment (from Stephen A. Moses, President, Center for Long-Term Care Reform):
Alzheimer’s research “outside the box.”

Beyond amyloid’: A look at what’s next in Alzheimer’s research

#goldencareagent
#alzheimers